The ACT Malaria Treatment Policy Change in Kenya by Akhwale, Willis S.
The ACT Malaria Treatment Policy Change 
in Kenya
THE IMPLEMENTATION PROCESS AND 
CHALLENGES
Dr. Willis S. Akhwale –Head
Division of Malaria Control
Ministry of Health,Kenya
Objectives of the national 
Antimalarial treatment policy
• Enable population at risk access safe, good 
quality, effective, affordable & acceptable 
antimalarial drugs
• Ensure rapid and long lasting clinical cure
• Prevent progression to severe disease
• Reduce the incidence of anaemia
• Reduce consequences of placental malaria 
infection
• Delay development of resistance to 
antimalarial drugs
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SP study Failures >= 25%
• 1996-1999 1/9 studies ACR < 75%
• 2000 6/11 studies ACPR < 75%
• 2001-2003 7/12 studies ACPR < 75%
• Day 14 to day 28 ACPR: 
– Bondo 62% vs.  35%
– Kibwezi 83% vs. 48%
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AQ study Failures >= 25%
• One study in 2001 ACPR < 75%
• Day 14 to day 28 ACPR: 
– Bondo 98% vs  87%
– Kibwezi 87% vs 62%
Makanga et al. 
ART-LUM (Coartem) studies –
Kilifi(under 5 y)
• Efficacy ACPR day 14 - 100% (n =92)
• Efficacy ACPR day 28 - 92%
• Effectiveness ACPR day 14 - 98% (n =85)
• Effectiveness ACPR day 28 - 92%
POLICY- Which drugs?
• 1.Uncomplicated Malaria—6 dose regimen of 
artemether-lumefantrine
• 2nd Line— Oral Quinine-7 day course
• Severe – Parentral quinine- 7 day course
• Malaria prevention in pregnancy (IPT)—SP
• Case management in Pregnancy-Quinine in all 
trimesters and artemether-lumefantrine may be 
used in 2nd and 3rd trimesters.
• Pre-referral management of severe malaria-
Quinine, artesunate suppositories and IM 
artemether
Chemoprophylaxis
• Long term residence-Proguanil 
(Paludrine)-1 week before & 4 weeks after.
• Mefloquine- 3 weeks before& 4 weeks 
after, Doxycycline- 100mg OD during stay 
and 4 weeks after (not children and 
pregnant women)
• Long term visitors advised to carry a 
treatment dose of coartem in case they 
cant access medical care
Diagnostics
• Need for parasitological diagnosis for 
older children and adults
• Introduction of Rapid Diagnostic Kits 
(RDTs) and interpretation of results in 
the different epidemiological settings
• QA/QC of microscopy and RDTs
• Prescriber habits
MOH Concerns and constraints
• Sustainability- assurance of GFATM 
commitment over 5 year period
• Budgetary commitment- yet to be 
included in the MTEF
• Cost differential in public vs private 
sectors
Key specific issues
• Limited data available on safety of ACTs in young infants 
(use of coartem <5kgs)
• Lack of adequate safety and efficacy data on drug 
combinations in pregnant women (safety of lumefantrine 
in pregnancy)
• Improving systems of forecasting of drug needs
• Strengthening the management and drug supply system 
(procurement, distribution and use) according to the 
specificities of the new drugs (shorter shelf life and the 
course-of-therapy packs)
• Complex treatment schedules poses challenge for ensuring 
compliance
• Need for more friendly paediatric formulations
Key specific issues contd.
• Complexity of regimens for treatment near 
the home
– Use of ACTs at community level
– Engaging and sustaining communities
– Improving malaria diagnosis at community 
level
– Involvement of the private sector 
Challenges
• Artemether-lumefantrine (Coartem®), patented and 
single-source 
• All other ACTs: multi-source products, generally off-
patent generics, available as individual products to 
be co-administered (preferably in course-of-therapy 
blister packs). 
• Market not primed - few manufacturers, limited 
experience with manufacturing and packaging of 
artemisinin derivatives (highly hygroscopic), API 
linked to natural plant production 
• Relatively new products on the international market 
– limited country experience in regulation and 
procurement
Malaria Case-Management Challenges
Only 11% of children access
antimalarial drugs within 48 hours
Sustainable financing of new 
expensive antimalarial drugs
Making new drugs available 
as close to home as possible
NO YES
Current status
• Nationwide implementation started 
in July 2006
• 9,000/17,000 core health workers 
trained
• 12.2 million treatment doses 
• 30% of doses issued to mission HF
Advocacy and communication 
campaign ongoing
Monitoring and evaluation
• Monitoring the Policy Change (The system)-key actions and 
clear deadlines
• Fframework for monitoring the implementation of the new drug 
policy developed
• Monitoring Availability and Quality of all ACTs on the market 
• Post-market surveillance to eliminate sub-standard drugs from 
the market,
• Prescribing and dispensing habits and dosage compliance 
• Therapeutic efficacy testing of ACTs: Conduct routine 
monitoring of Artemether- Lumefantrine, other potential ACTs 
and quinine
• Pharmacovigilance (adverse drug reaction monitoring). 
• HMIS of malaria morbidity and mortality data

